Anti-TAT 113 antibodies

• US 7,547,768 B2
• Filed: 11/20/2007
• Issued: 06/16/2009
• Est. Priority Date: 06/20/2001
• Status: Expired due to Fees

• Current Assignee: Genentech, Inc. (Roche Holding AG)
• Original Assignee: Genentech, Inc. (Roche Holding AG)
• Inventors: Frantz, Gretchen, Polakis, Paul, Smith, Victoria, Zhang, Zemin, Spencer, Susan D., Wu, Thomas D., Dowd, Patrick
• Primary Examiner(s): Blanchard; David J.
• Application Number:
  US11/943,454
• Publication Number:
  US 20080124739A1
• Time in Patent Office: 574 Days
• Field of Search: None
• US Class Current: 530/388.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.

Claims

1. An isolated monoclonal antibody that binds to the epitope bound by an antibody produced by any of the hybridoma cell lines selected from the group consisting of 12E5.1.1 (ATCC Accession No. PTA-6625) and 6G10.11 (ATCC Accession No. PTA-6623).

2. The antibody of claim 1 which is an antibody fragment.

3. The antibody of claim 1 which is a chimeric or a humanized antibody.

4. The antibody of claim 1 which is conjugated to a growth inhibitory agent.

5. The antibody of claim 1 which is conjugated to a cytotoxic agent.

6. The antibody of claim 5, wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.

7. The antibody of claim 5, wherein the cytotoxic agent is a toxin.

8. The antibody of claim 7, wherein the toxin is selected from the group consisting of maytansinoid and calicheamicin.

9. The antibody of claim 8, wherein the toxin is a maytansinoid.

10. The antibody of claim 1, which is produced in bacteria.

11. The antibody of claim 1, which is produced in CHO cells.

12. The antibody of claim 1, which induces death of a cell to which it binds.

13. The antibody of claim 1, which is detectably labeled.

14. The antibody of claim 1, which comprises six of the complementarity determining regions of any antibody produced by any of the hybridoma cell lines selected from the group consisting of 12E5.1.1 (ATCC Accession No. PTA-6625) and 6G10.11 (ATCC Accession No. PTA-6623).

15. A monoclonal antibody produced by any of the hybridoma cells selected from the group consisting of 12E5.1.1 (ATCC Accession No. PTA-6625) and 6G10.11 (ATCC Accession No. PTA-6623).

16. A hybridoma cell which produces a monoclonal antibody that binds to the polypeptide of SEQ ID NO:

2 wherein the hybridoma cell is selected from the group consisting of 12E5.1.1 (ATCC Accession No. PTA-6625) and 6G10.11 (ATCC Accession No. PTA-6623).